- Home
- PTCT
as 07-08-2024 3:34pm EST
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | 2.9B | IPO Year: | 2013 |
| Target Price: | $35.79 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Hold | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.53 - $42.63 | Next Earning Date: | 08-01-2024 |
| Revenue: | $927,558,000 | Revenue Growth: | 20.39% |
| Revenue Growth (this year): | -19.21% | Revenue Growth (next year): | 8.53% |
Stock Insider Trading Activity of PTC Therapeutics Inc. (PTCT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ZELDIS JEROME B | PTCT | Director | May 22 '24 | Sell | $38.24 | 20,000 | $764,800.00 | 14,500 | SEC Form 4 |
| Golden Lee Scott | PTCT | EVP & CHIEF MEDICAL OFFICER | May 7 '24 | Sell | $32.82 | 175 | $5,743.50 | 59,813 | SEC Form 4 |
| Klein Matthew B. | PTCT | CHIEF EXECUTIVE OFFICER | Apr 19 '24 | Sell | $24.89 | 3,361 | $83,668.73 | 225,807 | SEC Form 4 |
| Klein Matthew B. | PTCT | CHIEF EXECUTIVE OFFICER | Apr 17 '24 | Sell | $25.14 | 1,307 | $32,851.45 | 229,168 | SEC Form 4 |
| Pauwels Eric | PTCT | CHIEF EXECUTIVE OFFICER | Apr 17 '24 | Sell | $25.14 | 787 | $19,781.25 | 67,694 | SEC Form 4 |
| Golden Lee Scott | PTCT | EVP & CHIEF MEDICAL OFFICER | Apr 2 '24 | Sell | $28.37 | 526 | $14,922.62 | 59,988 | SEC Form 4 |
| Almstead Neil Gregory | PTCT | CHIEF TECHNICAL OPS OFFICER | Jan 30 '24 | Sell | $27.25 | 618 | $16,840.99 | 61,202 | SEC Form 4 |
| Almstead Neil Gregory | PTCT | CHIEF TECHNICAL OPS OFFICER | Jan 30 '24 | Sell | $27.25 | 28 | $763.02 | 3,706 | SEC Form 4 |
| Utter Christine Marie | PTCT | SVP, CHIEF ACCOUNTING OFFICER | Jan 30 '24 | Sell | $27.25 | 318 | $8,665.75 | 35,528 | SEC Form 4 |
| Boulding Mark Elliott | PTCT | EXEC. VP AND CLO | Jan 30 '24 | Sell | $27.25 | 794 | $21,637.14 | 71,189 | SEC Form 4 |
| Pauwels Eric | PTCT | CHIEF BUSINESS OFFICER | Jan 30 '24 | Sell | $27.25 | 366 | $9,973.79 | 44,181 | SEC Form 4 |
| Jacobson Allan Steven | PTCT | Director | Jan 22 '24 | Sell | $27.38 | 10,000 | $273,804.00 | 12,348 | SEC Form 4 |
| Klein Matthew B. | PTCT | CHIEF EXECUTIVE OFFICER | Jan 8 '24 | Sell | $29.01 | 5,443 | $157,927.56 | 160,475 | SEC Form 4 |
| Klein Matthew B. | PTCT | CHIEF EXECUTIVE OFFICER | Jan 8 '24 | Sell | $28.64 | 2,237 | $64,068.35 | 165,918 | SEC Form 4 |
| Golden Lee Scott | PTCT | CHIEF MEDICAL OFFICER | Jan 8 '24 | Sell | $28.64 | 775 | $22,196.23 | 39,139 | SEC Form 4 |
| Golden Lee Scott | PTCT | CHIEF MEDICAL OFFICER | Jan 8 '24 | Sell | $29.01 | 1,225 | $35,543.13 | 37,914 | SEC Form 4 |
| Almstead Neil Gregory | PTCT | CHIEF TECHNICAL OPS OFFICER | Jan 8 '24 | Sell | $28.64 | 1,236 | $35,399.41 | 63,341 | SEC Form 4 |
| Almstead Neil Gregory | PTCT | CHIEF TECHNICAL OPS OFFICER | Jan 8 '24 | Sell | $28.64 | 53 | $1,517.94 | 3,834 | SEC Form 4 |
| Almstead Neil Gregory | PTCT | CHIEF TECHNICAL OPS OFFICER | Jan 8 '24 | Sell | $29.01 | 1,521 | $44,131.51 | 61,820 | SEC Form 4 |
| Almstead Neil Gregory | PTCT | CHIEF TECHNICAL OPS OFFICER | Jan 8 '24 | Sell | $29.01 | 100 | $2,901.48 | 3,734 | SEC Form 4 |
| Utter Christine Marie | PTCT | SVP, FINANCE & CAO | Jan 8 '24 | Sell | $28.64 | 1,188 | $34,024.68 | 37,499 | SEC Form 4 |
| Utter Christine Marie | PTCT | SVP, FINANCE & CAO | Jan 8 '24 | Sell | $29.01 | 1,653 | $47,961.46 | 35,846 | SEC Form 4 |
| SCHMERTZLER MICHAEL | PTCT | Director | Jan 8 '24 | Sell | $27.81 | 1,500 | $41,715.00 | 115,266 | SEC Form 4 |
| Pauwels Eric | PTCT | CHIEF BUSINESS OFFICER | Jan 8 '24 | Sell | $28.64 | 1,569 | $44,936.63 | 46,612 | SEC Form 4 |
| Pauwels Eric | PTCT | CHIEF BUSINESS OFFICER | Jan 8 '24 | Sell | $29.01 | 2,065 | $59,915.56 | 44,547 | SEC Form 4 |
Latest PTC Therapeutics Inc. News
PTCT Breaking Stock News: Dive into PTCT Ticker-Specific Updates for Smart Investing
MT Newswires
7 days ago
Cantor Fitzgerald Raises Price Target on PTC Therapeutics to $62 From $52, Maintains Overweight Rating
Zacks
7 days ago
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
Investor's Business Daily
10 days ago
PTC's Journey Of 'Twist And Doubt' Continues With Another Rejection; Shares Tumble
MT Newswires
10 days ago
Update: PTC Therapeutics Shares Drop After Negative Opinion on Muscular Dystrophy Treatment
Investor's Business Daily
10 days ago
PTC Therapeutics Tumbles After European Regulators Reject Its Drug — Again
BioPharma Dive
10 days ago
PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
MT Newswires
10 days ago
PTC Therapeutics Shares Drop After Negative Opinion on Muscular Dystrophy Treatment
PR Newswire
10 days ago
CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review
Share on Social Networks:
Disclaimer
The information presented on this page, "PTCT PTC Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.